# Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT01962792** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 84 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01962792
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962792, "Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01962792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*